<DOC>
	<DOCNO>NCT01553656</DOCNO>
	<brief_summary>The purpose study evaluate safety profile , tolerability , pharmacokinetics ( PK ) , pharmacodynamics , pharmacogenomic ( PGX ) preliminary efficacy follow daily oral dos cabozantinib ( XL184 ) Japanese patient advanced metastatic solid tumor . Also , effect XL184 treatment non-small cell lung cancer ( NSCLC ) patient various activate mutation evaluate recommend Phase 2 dose .</brief_summary>
	<brief_title>Dose-Finding Study Cabozantinib ( XL184 ) Japanese Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Select Subjects advance metastatic solid tumor standard care ineffective inappropriate . NSCLC expansion cohort subject must confirm NSCLC ( Stage IIIb IV ) document activate mutation . At least 4 week must elapse last anticancer therapy . At least 6 week nitrosoureas , mitomycin C liposomal doxorubicin . Have adequate bone marrow function , adequate liver function , adequate renal function . Sexually active subject ( men woman childbearing potential ( WOCBP ) ) must agree use medically accept barrier method contraception ( eg , male female condom ) course study 4 month last dose study drug ( ) , even oral contraceptive also use . All subject reproductive potential must agree use barrier method second method birth control . Women childbearing potential ( WOCBP ) must negative pregnancy test screening . Select Symptomatic central nervous system ( CNS ) metastasis , active CNS metastasis require medication . WOCBP unwilling unable use acceptable method contraception avoid pregnancy entire study period 4 month last dose investigational product . Women pregnant breastfeeding . Sexually active fertile men use effective birth control entire study period 4 month last dose investigational product partner WOCBP . Subjects uncontrolled intercurrent illness include , limited , infection require systemic therapy , symptomatic congestive heart failure , uncontrolled hypertension , uncontrolled angina pectoris , uncontrolled peptic ulcer , cardiac arrhythmia require medication . Subjects HIV antibody positive , HBs antigen positive , and/or HCV antibody positive . Subjects body cavity fluid retention require drainage . Subjects major surgery within 8 week prior study enrollment . Subjects major unhealed wound fracture . Subjects history concurrent diagnosis gastrointestinal perforation . Subjects evidence bleeding tendency coagulopathy . Subjects history thromboembolism . Subjects history concurrent pancreatitis . Exposure investigational drug within 30 day enrollment . Subjects receive radiation therapy treatment radionuclides within 6 2 week first dose XL184 . NSCLC expansion cohort : subject must diagnose another malignancy within 2 year first dose XL184 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>NSCLC</keyword>
</DOC>